Literature DB >> 7087044

In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.

D D Mickey, G H Mickey, W M Murphy, H B Niell, M S Soloway.   

Abstract

Four longterm murine bladder tumor cell lines were established in vitro. The 4 lines were initiated from primary N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced murine bladder tumors arising in C3H/He mice. Each was maintained as a solid tumor in syngeneic mice for at least 30 generations before initiation in tissue culture. The cell lines MBT-2, MBT-8, MBT-409 and MBT-683, have been subcultured over 75 times in vitro for 18 months. They are all epithelial, grow in islands on plastic Petri dishes before confluent growth and form colonies in soft agar suspension culture. Morphologic studies indicate that all 4 lines have epithelial characteristics and karyotypic studies indicate that all lines have polyploidy and marker chromosomes. Population doubling times range from 10 to 26 hours and are consistent for each line.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7087044     DOI: 10.1016/s0022-5347(17)54305-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Role of the implantation site on metastatic ability of the murine MBT-2 transitional cell carcinoma.

Authors:  J E Klaunig; B A Barut
Journal:  Urol Res       Date:  1988

2.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

3.  Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro.

Authors:  H Yamada; E Kuroda; S Matsumoto; T Matsumoto; T Yamada; U Yamashita
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

5.  Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor.

Authors:  S A Kadhim; J Y Wang; B McLean; J L Chin
Journal:  Urol Res       Date:  1991

6.  Isolation and characterization of metastatic sublines from a murine transitional cell bladder carcinoma.

Authors:  B A Barut; J E Klaunig
Journal:  Clin Exp Metastasis       Date:  1986 Jan-Mar       Impact factor: 5.150

7.  Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro.

Authors:  H Yamada; S Matsumoto; T Matsumoto; T Yamada; U Yamashita
Journal:  Jpn J Cancer Res       Date:  2000-05

8.  Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.

Authors:  Chi-Ping Huang; Chun-Chie Wu; Chih-Rong Shyr
Journal:  Cancer Immunol Immunother       Date:  2020-11-06       Impact factor: 6.968

9.  The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression.

Authors:  Ho Kyung Seo; Seung-Phil Shin; Na-Rae Jung; Whi-An Kwon; Kyung-Chae Jeong; Sang-Jin Lee
Journal:  Oncotarget       Date:  2016-07-22

10.  Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Authors:  Makito Miyake; Shunta Hori; Sayuri Ohnishi; Michihiro Toritsuka; Tomomi Fujii; Takuto Shimizu; Takuya Owari; Yosuke Morizawa; Daisuke Gotoh; Yoshitaka Itami; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Cancer Sci       Date:  2019-08-19       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.